Therapeutic Drug Monitoring of Ticagrelor in Jordanian Patients. Development of Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class IV Drugs of Salivary Excretion Classification System (SECS).

Nasir Idkaidek

Makale detayları

Therapeutic Drug Monitoring of Ticagrelor in Jordanian Patients. Development of Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class IV Drugs of Salivary Excretion Classification System (SECS).

Yazarlar:

Nasir Idkaidek

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Sciences

Dergi:

Journal of Research in Pharmacy Vol.26 Issue 5, pp.1411-1419

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001347559

pISSN:

2630-6344

Anahtar kelimeler:

Özet:

 Ticagrelor is an orally administered antiplatelet agent that has been approved for the reduction of cardiovascular risk in patients with history of cardiovascular disease. However, Ticagrelor can also cause adverse effects, including dyspnea. Ticagrelor plasma and saliva concentrations of 63 Jordanian patients were measured using a sensitive LCMSMS method. Ticagrelor was not excreted in saliva as it corresponds to the Class IV salivary excretion classification system. The correlation between plasma ticagrelor concentrations and the occurrence of dyspnea was examined to establish a therapeutic window for plasma ticagrelor. A physiologically-based pharmacokinetic PBPK model of ticagrelor was built and validated using previously- published plasma data. The validated model was then used to predict the factors affecting ticagrelor plasma concentrations. A loading dose of 135 mg 1.5 tablet instead of 2 tablets has been suggested to maintain its therapeutic effect and avoid dyspnea.

 Ticagrelor is an orally administered antiplatelet agent that has been approved for the reduction of cardiovascular risk in patients with history of cardiovascular disease. However, Ticagrelor can also cause adverse effects, including dyspnea. Ticagrelor plasma and saliva concentrations of 63 Jordanian patients were measured using a sensitive LCMSMS method. Ticagrelor was not excreted in saliva as it corresponds to the Class IV salivary excretion classification system. The correlation between plasma ticagrelor concentrations and the occurrence of dyspnea was examined to establish a therapeutic window for plasma ticagrelor. A physiologically-based pharmacokinetic PBPK model of ticagrelor was built and validated using previously- published plasma data. The validated model was then used to predict the factors affecting ticagrelor plasma concentrations. A loading dose of 135 mg 1.5 tablet instead of 2 tablets has been suggested to maintain its therapeutic effect and avoid dyspnea.

 Ticagrelor is an orally administered antiplatelet agent that has been approved for the reduction of cardiovascular risk in patients with history of cardiovascular disease. However, Ticagrelor can also cause adverse effects, including dyspnea. Ticagrelor plasma and saliva concentrations of 63 Jordanian patients were measured using a sensitive LCMSMS method. Ticagrelor was not excreted in saliva as it corresponds to the Class IV salivary excretion classification system. The correlation between plasma ticagrelor concentrations and the occurrence of dyspnea was examined to establish a therapeutic window for plasma ticagrelor. A physiologically-based pharmacokinetic PBPK model of ticagrelor was built and validated using previously- published plasma data. The validated model was then used to predict the factors affecting ticagrelor plasma concentrations. A loading dose of 135 mg 1.5 tablet instead of 2 tablets has been suggested to maintain its therapeutic effect and avoid dyspnea.

 Ticagrelor is an orally administered antiplatelet agent that has been approved for the reduction of cardiovascular risk in patients with history of cardiovascular disease. However, Ticagrelor can also cause adverse effects, including dyspnea. Ticagrelor plasma and saliva concentrations of 63 Jordanian patients were measured using a sensitive LCMSMS method. Ticagrelor was not excreted in saliva as it corresponds to the Class IV salivary excretion classification system. The correlation between plasma ticagrelor concentrations and the occurrence of dyspnea was examined to establish a therapeutic window for plasma ticagrelor. A physiologically-based pharmacokinetic PBPK model of ticagrelor was built and validated using previously- published plasma data. The validated model was then used to predict the factors affecting ticagrelor plasma concentrations. A loading dose of 135 mg 1.5 tablet instead of 2 tablets has been suggested to maintain its therapeutic effect and avoid dyspnea.

Makale detayları

Therapeutic Drug Monitoring of Ticagrelor in Jordanian Patients. Development of Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class IV Drugs of Salivary Excretion Classification System (SECS).

Yazarlar:

Nasir Idkaidek

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Sciences

Dergi:

Journal of Research in Pharmacy Vol.26 Issue 5, pp.1411-1419

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001347559

pISSN:

2630-6344

Ticagrelor

pharmacokinetics

SECS

TDM

Gastroplus

PBPK

Sayı

Makale detayları

Therapeutic Drug Monitoring of Ticagrelor in Jordanian Patients. Development of Physiologically-Based Pharmacokinetic (PBPK) Model and Validation of Class IV Drugs of Salivary Excretion Classification System (SECS).

Yazarlar: Nasir Idkaidek

Yayıncı: Marmara University

Ana Başlıklar: Pharmaceutical Sciences

Dergi: Journal of Research in Pharmacy Vol.26 Issue 5, pp.1411-1419

Belge Tipi: Makale

Yayın Tarihi: 6/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001347559

pISSN: 2630-6344

Ticagrelor

pharmacokinetics

SECS

TDM

Gastroplus

PBPK

Sayı

Yazarlar:

Nasir Idkaidek

Yayıncı:

Marmara University

Ana Başlıklar:

Pharmaceutical Sciences

Dergi:

Journal of Research in Pharmacy Vol.26 Issue 5, pp.1411-1419

Belge Tipi:

Makale

Yayın Tarihi:

6/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001347559

pISSN:

2630-6344